Patient characteristics and drug utilization of heart failure patients prescribed SGLT2i and sacubitril/valsartan, a real-world database cohort study of Optum electronic health record data source

被引：0
|
作者：
Loefroth, E. [1 ]
Hughes, M. [2 ]
Wang, Y. [3 ]
Shi, Y. [3 ]
Proudfoot, C. [4 ]
Di Domenico, M. [4 ]
Modgill, V. [4 ]
Schlienger, R. [4 ]
Studer, R. [4 ]
机构：
[1] Novartis Sverige AB, Stockholm, Sweden
[2] Novartis Ireland Ltd, Dublin, Ireland
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharma AG, Basel, Switzerland
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1557
引用
收藏
页码：273 / 273
页数：1
相关论文
共 19 条
  • [1] Patient and clinical characteristics of heart failure patients concomitantly prescribed SGLT2 inhibitors and sacubitril/valsartan, a database cohort study using the Optum electronic health record data
    Loefroth, E.
    Hughes, M.
    Shi, Y.
    Wang, Y.
    Proudfoot, C.
    Di Domenico, M.
    Modgill, V
    Schlienger, R.
    Studer, R.
    EUROPEAN HEART JOURNAL, 2020, 41 : 981 - 981
  • [2] Drug Utilization Study in Heart Failure (HF) Patients Concomitantly Prescribed Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) and Sacubitril/valsartan (sac/val), a Database Cohort Study Using Optum Electronic Health Record (EHR) US Data
    Loefroth, Emil
    Hughes, Maria
    Shi, Yulin
    Wang, Yitong
    Proudfoot, Clare
    Domenico, Maximiliano D.
    Modgill, Vikas
    Schlienger, Raymond
    Studer, Rachel
    CIRCULATION, 2020, 142
  • [3] Comparison of Heart Failure Patients Newly Prescribed Sacubitril/valsartan With Those Newly Prescribed Aceis/arbs; A Cohort Study Using Us Optum Electronic Health Record Data
    Loefroth, Emil
    Shen, Xian
    Studer, Rachel
    Schlienger, Raymond
    Proudfoot, Clare
    Corda, Stefano
    Saha, Sibasish
    Satwase, Sarvesh K.
    Houchen, Emma
    CIRCULATION, 2020, 142
  • [4] SACUBITRIL/VALSARTAN REAL-WORLD PERSISTENCE USING A COHORT OF HEART FAILURE PATIENTS FROM THE PRESCRIPTION & MONITORING OF SACUBITRIL/VALSARTAN STUDY (PRIME 2 STUDY)
    Teixeira Rodrigues, A.
    Murteira, R.
    Bulhosa, C.
    Cary, M.
    Guerreiro, J.
    Laires, P. A.
    Afonso-Silva, M.
    VALUE IN HEALTH, 2020, 23 : S505 - S505
  • [5] Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
    Ganesananthan, Sashiananthan
    Shah, Nisar
    Shah, Parin
    Elsayed, Hossam
    Phillips, Julie
    Parkes, Ann
    Morgan, Angharad
    Yousef, Zaheer
    OPEN HEART, 2020, 7 (02):
  • [6] Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry
    Zeymer, Uwe
    Clark, Andrew L.
    Barrios, Vivencio
    Damy, Thibaud
    Drozdz, Jaroslaw
    Fonseca, Candisda
    Lund, Lars H.
    Kalus, Stefanie
    Ferber, Philippe C.
    Hussain, Rizwan, I
    Koch, Cornelia
    Maggioni, Aldo P.
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2022, 8 (04) : 469 - 477
  • [7] An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction
    Antol, Dana Drzayich
    Casebeer, Adrianne Waldman
    DeClue, Richard W.
    Stemkowski, Stephen
    Russo, Patricia A.
    ADVANCES IN THERAPY, 2018, 35 (06) : 785 - 795
  • [8] An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction
    Dana Drzayich Antol
    Adrianne Waldman Casebeer
    Richard W. DeClue
    Stephen Stemkowski
    Patricia A. Russo
    Advances in Therapy, 2018, 35 : 785 - 795
  • [9] Baseline characteristics and alterations after initiation of therapy with SGLT2i in a real-world heart failure with reduced ejection fraction population
    Stavrati, A.
    Polymeropoulos, K.
    Ioannidis, P.
    Kleitsioti, P.
    Lazaridis, P.
    Zarifis, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 163 - 163
  • [10] SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series
    Zampieri, Mattia
    Argiro, Alessia
    Allinovi, Marco
    Perfetto, Federico
    Cappelli, Francesco
    INTERNAL AND EMERGENCY MEDICINE, 2022, 17 (04) : 1243 - 1245
12